Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Jun 12, 2019 → May 1, 2038
NCT ID
NCT03989947About Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. is a phase 2 stage product being developed by BioMarin Pharmaceutical for Achondroplasia. The current trial status is active. This product is registered under clinical trial identifier NCT03989947. Target conditions include Achondroplasia.
What happened to similar drugs?
0 of 3 similar drugs in Achondroplasia were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03989947 | Phase 2 | Active |
Competing Products
20 competing products in Achondroplasia